Topic 130

antibodies elisa serological cov sars covid igg assay 19 antibody sera spike serum antigens neutralization assays against immunology diagnosis neutralizing serology infection pcr igm antigen samples coronavirus pandemic sensitivity specificity 100 iga plasma recombinant 2019 detection reactivity prevalence virus testing convalescent immunosorbent diagnostic seroprevalence positive rbd negative viral cross coronaviruses tests detecting test titers disease need specimens confirmed collected protein s1 domain rapid clinical titer microbiology euroimmun validation infections standard sensitivities binding days 93 plaque nucleoprotein 98 specificities evaluation severe respiratory measure gold vaccine 96 receptor tested mers detected donors laboratories quantitative patient detect epidemiologic anti immunity nasopharyngeal values using

40 items. Top items listed below.

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples 130 24 1

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies 130 35 1

Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity 130 35 1

SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation 130 103 1

Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray 130 1

Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. 130 24 1

High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization. 130 24 1

Role of Anti-SARS-CoV-2 antibodies in different cohorts: Can they provide clues for appropriate patient triaging? 130 35 1

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. 130 35 1

Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens 130 24 1

Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples 130 35 1

Clinical And Analytical Performance Of An Automated Serological Test That Identifies S1/S2 Neutralizing IgG In Covid-19 Patients Semiquantitatively. 130 35 24 1

Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray 130 24 1

Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays 130 35 1

Validation and performance of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies 130 24 1

Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2 130 24 1

High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform 130 24 1

Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein 130 24 1

Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera 130 1

Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance 130 1

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. 24 1

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation 130 24 1

A rapid, point of care red blood cell agglutination assay for detecting antibodies against SARS-CoV-2 130 1

A simple protein-based surrogate neutralization assay for SARS-CoV-2 36 24 1

In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19 130 35 1

Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals 130 103 1

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India 24 1

Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray 130 24 1

Association between neutralizing antibodies to SARS-CoV-2 and commercial serological assays 130 7 1

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients 24 1

Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein 24 1

Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay 130 1

A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds 130 1

Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19 130 73 1

A comparison of non-magnetic and magnetic beads for measuring IgG antibodies against P. vivax antigens in a multiplexed bead-based assay using Luminex(R) technology (Bio-Plex(R)200 or MAGPIX(R)) 130 24 1

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike 24 1

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins 130 24 1

SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan 24 1

Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay 24 1

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 24 1

Discriminative Bayesian Serology: Counting Without Cutoffs 130 83 35 4

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples 24 1

Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays 130 24 1

SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts 103 1

Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans 24 1

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma 24 1

The Theory and Practice of the viral dose in neutralization assay: insights on SARS-CoV-2 "doublethink" effect. 35 1

Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities 130 35 24 18 4

Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients 24 1

Currently available intravenous immunoglobulin (Gamunex(C)-C and Flebogamma(C) DIF) contains antibodies reacting against SARS-CoV-2 antigens 130 1

S protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit 24 1

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement 36 24 1

Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy 24 1

Preclinical study of DNA vaccines targeting SARS-CoV-2 24 1

Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia 130 15 1

SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with non-severe disease 130 1

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections 24 1

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 36 1

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection 103 1

Development of Reverse Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-2 35 1

Brief Communication: Magnetic Immuno-Detection of SARS-CoV-2 specific Antibodies 130 35 18

Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells 36 24 1

Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection 35 1

Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection 24 1

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies 36 24 1

The immunodominant and neutralization linear epitopes for SARS-CoV-2 24 1

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses 24 1

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors 24 1

SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution 76 24 1

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike 24 1

Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals 24 1

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection 24 1

Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients 24 1

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 24 1

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals 24 1

SARS-CoV-2 Elicits Robust Adaptive Immune Responses Regardless of Disease Severity 24 1

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 24 1

Development of a reverse transcription polymerase chain reaction for the detection of severe fever with thrombocytopenia syndrome virus from suspected infected animals 35 1

Abnormal Antibodies to Self-Carbohydrates in SARS-CoV-2 Infected Patients 1

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans 24 1

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection 24 1

Robust and sensitive detection of SARS-CoV-2 using PCR based methods 35 1

Evaluation of Different PCR Assay Formats for Sensitive and Specific Detection of SARS-CoV-2 RNA 35 1

AI334 and AQ806 antibodies recognize the spike S protein from SARS-CoV-2 by ELISA 130 24 1

A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition 24 1

SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease 24 1

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries 36 24 1

Use of convalescent serum reduces severity of COVID-19 in nonhuman primates 24 1

Development of a high-throughput homogeneous AlphaLISA drug screening assay for the detection of SARS-CoV-2 Nucleocapsid 103 44 1

Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients 24 1

A valid protective immune response elicited in rhesus macaques by an inactivated vaccine is capable of defending against SARS-CoV-2 infection 24 1

Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies 1

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein 24 1

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability 36 24 1

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. 24 1

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response 24 1

Estimating cumulative incidence of SARS-CoV-2 with imperfect serological tests: a cutoff-free approach 83 4

Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2 1

NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response 24 1

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells 103 36 1